Navigation Links
SpideRX® Embolic Protection Device

ProductsSpideRX® Embolic Protection Device
Company ev3, Inc.
Item SpideRX® Embolic Protection Device
Features 
  • Pre-Loaded Filter/Capture Wire - Ready to flush and deploy with no stylet or introducer needed
  • Fully Rapid Exchange - For quick delivery and recovery
  • 6 Fr Guide Catheter Compatible (minimum 0.066" I.D.) - To use with desired interventional devices
  • Use of Separate Preferred 0.014" - 0.018" Guidewire - Reliable access and tight lesion crossing in straight and tortuous anatomy
  • Single Dual-Ended Low-Profile Catheter - Fewer components to manage during procedure
  • Low 3.2 Fr Crossing profile - Minimal interaction with the lesion during catheter placement
  • Unique Nitinol Filter Design - Provides full body wall apposition, and the ability to capture debris
  • Multiple Filter Sizes (3.0, 4.0, 5.0, 6.0, 7.0 mm) - Optimal matching of the filter to the vessel size
  • Longitudinal/Rotational Wire Movement - Filter designed to remain stationary during the intervention and device exchanges
  • Radiopaque Gold Proximal Marker - Visualization of filter apposition throughout intervention
  • 4.2 Fr Recovery Catheter - Easily accommodates filter with debris
  • Rapid Exchange Recovery Catheter - For easy recovery after intervention
Description The SpideRX Embolic Protection Device features the ability to use a separate, preferred guidewire to cross the lesion and a pre-loaded nitinol filter with a dual-ended catheter for delivery and recovery. Offering a fully rapid exchange system, the SpideRX Device is easy to use in the indicated applications:

Carotid Indication - The SpideRX Embolic Protection Device is indicated for use as a guidewire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries. The diameter of the artery at the site of filter basket placement should be between 3.0 mm and 7.0 mm.

SVG Indication - The SpideRX Embolic Protection Device is indicated for use as an embolic protection system to contain and remove embolic material (thrombus/debris). The device also acts as the guidewire while performing percutaneous transluminal coronary angioplasty or stenting procedures in coronary saphenous vein bypass grafts with reference vessel diameters of 3.0 to 6.0 mm. The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral and peripheral vasculature.

Info ev3, Inc.
Customer Service: (800) 716-6700
Web site: http://www.ev3.net

Related medicine products :

1. Proxis Embolic Protection System
2. FilterWire EZ Embolic Protection System
3. RX ACCUNET Embolic Protection System
4. Emboshield(R) Embolic Protection System
5. Emboshield BareWire Embolic Protection System
6. Onyx® Liquid Embolic System
7. BD Visitec Eye Protection Products
8. T4 Personal Protection System
9. Qualcraft™ Lead-Free Back-Aid Radiation Protection Apron
10. QualCraft™ Radiation Protection Eyewear -- Metal
11. Radiation Protection Eyewear
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products:
(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...
(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...
(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...
(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...
Breaking Medicine News(10 mins):Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3
...sity in Caracas found that Lactobacillus casei (L ...d its flatulence capacity// and increased the nutr... nutrition especially in the developing countries....eam to analyze the method of creating flatulence-f...
...come into force in September 2006, will allow pati... to receive organs// from living donors who are un...allowed between people who are genetically or emot...nced by the by the Human Tissue Authority, which w...
...ify that the complete cancer has been removed at b...shed in the May issue of Radiology.// Researchers ... electromagnetic spectrum--the terahertz region--t...rmine if the removed tissue margins were clear of ...
...rsity researchers suggests that injuries related t...e emergency department//. Wearing of protective ey...isk of eye injury can avoid such instances. The r...d 2003, some 27,000 people went to the emergency d...
Other Medicine News:Health News:New Hope For Patients Needing Kidney Transplants In UK 2Health News:Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments 2Health News:Watch Out! Eye Glass Related Injuries On The Rise 2Health News:Watch Out! Eye Glass Related Injuries On The Rise 3
(Date:8/17/2008)...- Pharmaxis,(ASX: PXS; Nasd...hase 3,clinical trial of Bronchitol for the treatm...The first efficacy data from the trial is expected...e trial commenced its dosing phase in,April 2007, ...ects in June,2008 and closed today with 325 subjec...
(Date:8/14/2008)... showing clinical benefit in cancer,patients; Blin... and attack cancer ce.../ -- Micromet, Inc.,(Nasdaq: MITI ), a biopharmac...bodies for the treatment of cancer, inflammation a...n of a Phase 1 clinical study(1) on its,BiTE(R) an...
(Date:8/13/2008)...all/ -- As biotechnology,pharmaceutical and medic...als beyond their own borders to other parts of the...rica, complicated regulatory environments,challeng...o an analysis by,Aon Corporation (NYSE: AOC ). Ao...ompanies a visual representation of the complex in...
(Date:8/13/2008).../ -- Today positron emission,tomography (PET) scan...gy,tool for diagnosis, staging and monitoring. It ...logy emitting a radioactive tracer to localize,tum...normal tissue. As a,result, the malignant tissue s... spot.", The use of multiple imaging technologies...
Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring? 2Seeking sustainability in a world of instability 2198 1Seeking sustainability in a world of instability 2198 2Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 1Duragesic Trials Continue Plaintiffs Optimistic After Latest Recall 11870 2Cancer Drug Works Against MS in Early Trial 11869 1Cancer Drug Works Against MS in Early Trial 11869 2Cancer Drug Works Against MS in Early Trial 11869 3Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results 3275 1
...wire-FirstCall/ -- Vical,Incorporated today announ...ith the company,s Vaxfectin(TM) adjuvant generated...nformulated vaccine,at the same dose in a recently...steur,s Fluzone(R) commercial vaccine with,Vaxfect...vaccine,dose while generating equivalent or better...
...Apr 10, 2007 - Valeant,Pharmaceuticals Internation...hase 2 data for retigabine, a first-in-class,neuro...ing,independent, scientific journal. The authors c...monstrated reduction in monthly,seizure rates in t...d RESTORE2) are currently underway to further inve...
Other Medicine Technology:Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3